Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report describes a case of severe hair loss with accompanying thyroid issues and eczema that improved noticeably after individualized homeopathic treatment, following unsuccessful previous methods, as observed at Dr Batra’s® Homeopathy Clinic.

This study demonstrated that intramuscular corticosteroids were effective for severe alopecia areata, with significant hair regrowth in 80.2% of patients, though a high relapse rate was noted post-treatment. Nail involvement and disease duration over six months negatively impacted outcomes.

In this analysis of the BRAVE-AA trials, a significant number of patients with severe alopecia areata treated with baricitinib reached complete or nearly complete scalp coverage (SALT score ≤10 or ≤5) over 52 weeks, particularly among those with less severe baseline characteristics.

The abstract provides a brief mention of alopecia areata (AA) being a chronic immune-mediated disorder causing non-scarring hair loss, but specific study results or findings relating to this are not reported.

In this single-cell transcriptomic study, researchers analyzed AA scalp samples and found distinct immune and nonimmune cell activation patterns, with elevated TH1/TH2 and JAK/STAT markers potentially contributing to hair follicle immune privilege disruption and disease severity.

In this report, the sighting of a maned wolf in a rural area of Brazil with severe hair loss, likely due to alopecia, was documented, and it was suspected that the condition resulted from disease transmission from domestic dogs.

In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

This study suggests that autoimmune dysregulation involving HLA-DR+ T and NK cell subsets may contribute to severe patchy alopecia areata and alopecia universalis, with normalization seen after betamethasone treatment.

This study observed that the rs231775 CTLA4 genetic variant was more prevalent in Alopecia Areata patients than controls, particularly among those with severe disease.

In this study, researchers found that the absence of type I or type II keratins in mice leads to severe skin barrier defects, highlighting keratins' crucial role in epidermal structure and function.

This study identified a new genetic locus, ahl4, on distal Chromosome 10 that contributes to the early-onset, severe hearing loss in A/J mice compared to B6 mice.

This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.

This study found that baricitinib, when administered consistently over three years, maintained its efficacy in patients with severe alopecia areata who responded by Week 52 with notable hair regrowth, indicated by a SALT score of ≤20.

This study observed that patients with severe alopecia areata treated with baricitinib experienced increases in total cholesterol, LDL-C, and HDL-C, consistent with a JAK inhibitor class effect, but the mean increase was modest and lipid-lowering medication initiation was infrequent.

This study of baricitinib in adults with severe alopecia areata found that after initial success, 10.9% of participants lost treatment response by Week 152. Factors like longer disease duration and severe baseline symptoms were more common in those losing response.

This study aims to assess the real-world effectiveness of baricitinib, a JAK inhibitor, for promoting regrowth of nasal, genital, and beard hair in patients with severe alopecia areata, expanding on findings from the BRAVE-AA clinical trial. Results are not reported.

In this study, NH Asian alopecia areata patients reported the highest levels of severe disease, with NH White patients having the most eyebrow involvement and Hispanic patients showing the least severity.

In this study, 70.7% of long-COVID patients reported persistent symptoms three months post-infection, with chronic fatigue, cough, and brain fog being the most common, and female gender and severe initial COVID-19 were identified as risk factors.

In this review, platelet concentrates were found to show comparable efficacy to steroids and immunosuppressive drugs in treating oral lichen planus, with some studies reporting more benefits and others noting more severe adverse reactions with platelet treatments.

In this phase 3 trial analysis, baricitinib improved scalp hair growth in adults with severe alopecia areata, with a faster and higher response in those receiving 4 mg compared to 2 mg, but response varied with severity at baseline and continued through week 52.

In this study, baricitinib, a JAK inhibitor, was found to significantly improve scalp hair regrowth in both adults and adolescents with severe alopecia areata, with many achieving nearly full regrowth by weeks 36 or 52.

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

Different people with severe hair loss respond to baricitinib treatment at different times, with some showing improvement early, some gradually, and others later.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This clinical report details the case of a 22-year-old man experiencing severe pustular eruptions on his chest and back, which improved after increasing minocycline to 100 mg twice daily.

This study found that severe forms of alopecia areata may be associated with poor treatment response, particularly in cases with extensive hair loss, juvenile onset, or nail changes.

This review provides graded evidence and a therapeutic algorithm for managing hidradenitis suppurativa, but does not present new clinical results.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

Most men prefer keeping their eyebrows over scalp hair.